1.4 Scientific symposia: Improving access to care for leishmaniasis patients and its various forms (VL, CL, PKDL, HIV-VL), including vulnerable groups: the LeishAccess project

Session detail

Organiser:  Foundation of Innovative and New Diagnostics (FIND), Switzerland

Facilitate the uptake and adoption of new diagnostics and treatment options for VL, HIV-VL, and PKDL through systematic, targeted and measurable interventions

Speakers:
  • Simon Bolo, Drugs for Neglected Diseases initiative (DNDi), Kenya

Evaluation of rK28 and Kala-azar Detect rK39 rapid diagnostic tests for VL in Kenya, towards strengthening recommendations for their use and access in Eastern Africa

Speakers:
  • Dawn Maranga, FIND, Kenya

Phase II/ III, Open-Label, Multicenter, Randomized Clinical Trial to Evaluate the Safety and Efficacy of Thermotherapy for the Treatment of Uncomplicated Cutaneous Leishmaniasis Cases

Speakers:
  • Endalamaw Gadisa, Armauer Hansen Research Institute, Ethiopia

Assessment of burden, risk factors, knowledge and practices associated with VL among pastoralists

Speakers:
  • Rose Bosire, Kenya Medical Research Institute (KEMRI), Kenya

Evaluation of measures to improve access to care through decentralization of VL diagnosis and treatment in Turkana County

Speakers:
  • Jane Mbui, Kenya Medical Research Institute (KEMRI), Kenya
  • Dawn Maranga, FIND, Kenya